The current study explores the antimycobacterial efficacy of lichen-derived psoromic acid (PA) against clinical strains of Mycobacterium tuberculosis (M.tb). Additionally, the inhibitory efficacy of PA against two critical enzymes associated with M.tb, namely, UDP-galactopyranose mutase (UGM) and arylamine-N-acetyltransferase (TBNAT), as drug targets for antituberculosis therapy were determined. PA showed a profound inhibitory effect towards all the M.tb strains tested, with minimum inhibitory concentrations (MICs) ranging between 3.2 and 4.1 µM, and selectivity indices (SIs) ranging between 18.3 and 23.4. On the other hand, the standard drug isoniazid (INH) displayed comparably high MIC values (varying from 5.4 to 5.8 µM) as well as low SI values (13.0⁻13.9). Interestingly, PA did not exhibit any cytotoxic effects on a human liver hepatocellular carcinoma cell line even at the highest concentration tested (75 µM). PA demonstrated remarkable suppressing propensity against UGM compared to standard uridine-5'-diphosphate (UDP), with 85.8 and 99.3% of inhibition, respectively. In addition, PA also exerted phenomenal inhibitory efficacy (half maximal inhibitory concentration (IC50) value = 8.7 µM, and 77.4% inhibition) against TBNAT compared with standard INH (IC50 value = 6.2 µM and 96.3% inhibition). Furthermore, in silico analysis validated the outcomes of in vitro assays, as the molecular interactions of PA with the active sites of UGM and TBNAT were unveiled using molecular docking and structure⁻activity relationship studies. Concomitantly, our findings present PA as an effective and safe natural drug plausible for use in controlling tuberculosis infections.

Department of Applied Ecology Faculty of Environmental Sciences Czech University of Life Sciences Prague Kamýcká 129 165 21 Praha 6 Suchdol Czech Republic

Department of Biotechnology Science Campus Alagappa University Karaikudi 630003 India

Department of Natural Drugs Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Palackého tř 1946 1 612 42 Brno Czech Republic

Museum of literature in Moravia Klášter 1 664 61 Rajhrad Czech Republic

REEF Environmental Consultancy Services 2 Kamaraj Street S P Nagar Puducherry 605 001 India

Zobrazit více v PubMed

Raj R., Biot C., Carrère-Kremer S., Kremer L., Guérardel Y., Gut J., Rosenthal P.J., Forge D., Kumar V. 7-chloroquinoline–isatin conjugates: Antimalarial, antitubercular, and cytotoxic evaluation. Chem. Biol. Drug Des. 2014;83:622–629. doi: 10.1111/cbdd.12273. PubMed DOI

World Health Organization Fact Sheet on Tuberculosis (Updated January 2018) [(accessed on 30 January 2018)]; Available online: http://www.who.int/en/news-room/fact-sheets/detail/tuberculosis.

WHO Drug-Resistant TB: Global Situation. [(accessed on 30 January 2018)];2018 Available online: http://www.who.int/tb/areas-of-work/drug-resistant-tb/global-situation/en/

Herrmann J., Rybniker J., Müller R. Novel and revisited approaches in antituberculosis drug discovery. Curr. Opin. Biotechnol. 2017;48:94–101. doi: 10.1016/j.copbio.2017.03.023. PubMed DOI

Dong M., Pfeiffer B., Altmann K.-H. Recent developments in natural product-based drug discovery for tuberculosis. Drug Discov. Today. 2017;22:585–591. doi: 10.1016/j.drudis.2016.11.015. PubMed DOI

Young D.B., Perkins M.D., Duncan K., Barry C.E. Confronting the scientific obstacles to global control of tuberculosis. J Clin. Investig. 2008;118:1255–1265. doi: 10.1172/JCI34614. PubMed DOI PMC

Borrelli S., Zandberg W.F., Mohan S., Ko M., Martinez-Gutierrez F., Partha S.K., Sanders D.A., Av-Gay Y., Pinto B.M. Antimycobacterial activity of UDP-galactopyranose mutase inhibitors. Int. J. Antimicrob. Agents. 2010;36:364–368. doi: 10.1016/j.ijantimicag.2010.06.030. PubMed DOI

Del Campo J.S.M., Eckshtain-Levi M., Vogelaar N.J., Sobrado P. Identification of Aspergillus fumigatus UDP-Galactopyranose mutase inhibitors. Sci. Rep. 2017;7:10836. doi: 10.1038/s41598-017-11022-5. PubMed DOI PMC

Tanner J.J., Boechi L., McCammon J.A., Sobrado P. Structure, mechanism, and dynamics of udp-galactopyranose mutase. Arch. Biochem. Biophys. 2014;544:128–141. doi: 10.1016/j.abb.2013.09.017. PubMed DOI PMC

Fu J., Fu H., Dieu M., Halloum I., Kremer L., Xia Y., Pan W., Vincent S.P. Identification of inhibitors targeting Mycobacterium tuberculosis cell wall biosynthesis via dynamic combinatorial chemistry. Chem. Commun. 2017;53:10632–10635. doi: 10.1039/C7CC05251K. PubMed DOI

Villaume S.A., Fu J., N’Go I., Liang H., Lou H., Kremer L., Pan W., Vincent S.P. Natural and synthetic flavonoids as potent Mycobacterium tuberculosis UGM inhibitors. Chem. Eur. J. 2017;23:10423–10429. doi: 10.1002/chem.201701812. PubMed DOI

Partha S.K., Sadeghi-Khomami A., Slowski K., Kotake T., Thomas N.R., Jakeman D.L., Sanders D.A. Chemoenzymatic synthesis, inhibition studies, and x-ray crystallographic analysis of the phosphono analog of UDP-galp as an inhibitor and mechanistic probe for UDP-galactopyranose mutase. J. Mol. Biol. 2010;403:578–590. doi: 10.1016/j.jmb.2010.08.053. PubMed DOI

Westwood I.M., Bhakta S., Russell A.J., Fullam E., Anderton M.C., Kawamura A., Mulvaney A.W., Vickers R.J., Bhowruth V., Besra G.S. Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars. Protein Cell. 2010;1:82–95. doi: 10.1007/s13238-010-0006-1. PubMed DOI PMC

Butcher N.J., Tiang J., Minchin R.F. Regulation of arylamine N-acetyltransferases. Curr. Drug Metab. 2008;9:498–504. doi: 10.2174/138920008784892128. PubMed DOI

Madikane V.E., Bhakta S., Russell A.J., Campbell W.E., Claridge T.D., Elisha B.G., Davies S.G., Smith P., Sim E. Inhibition of mycobacterial arylamine N-acetyltransferase contributes to anti-mycobacterial activity of Warburgia salutaris. Bioorg. Med. Chem. 2007;15:3579–3586. doi: 10.1016/j.bmc.2007.02.011. PubMed DOI

Sim E., Sandy J., Evangelopoulos D., Fullam E., Bhakta S., Westwood I., Krylova A., Lack N., Noble M. Arylamine N-acetyltransferases in mycobacteria. Curr. Drug Metab. 2008;9:510–519. doi: 10.2174/138920008784892100. PubMed DOI PMC

Sim E., Pinter K., Mushtaq A., Upton A., Sandy J., Bhakta S., Noble M. Arylamine N-acetyltransferases: A pharmacogenomic approach to drug metabolism and endogenous function. Biochem. Soc. Trans. 2003;31:615–619. doi: 10.1042/bst0310615. PubMed DOI

Sweidan A., Chollet-Krugler M., Sauvager A., Van de Weghe P., Chokr A., Bonnaure-Mallet M., Tomasi S., Bousarghin L. Antibacterial activities of natural lichen compounds against Streptococcus gordonii and Porphyromonas gingivalis. Fitoterapia. 2017;121:164–169. doi: 10.1016/j.fitote.2017.07.011. PubMed DOI

Vartia K.O. The Lichens. Academic Press, Inc.; New York, NY, USA: 1973. Antibiotics in lichens; pp. 547–561.

Shibata S. Der stoffwechsel sekundärer pflanzenstoffe/the Metabolism of Secondary Plant Products. Springer; Berlin, Heidelberg, Germany: 1958. Especial compounds of lichens; pp. 560–623.

Emsen B., Aslan A., Togar B., Turkez H. In vitro antitumor activities of the lichen compounds olivetoric, physodic and psoromic acid in rat neuron and glioblastoma cells. Pharm. Biol. 2016;54:1748–1762. doi: 10.3109/13880209.2015.1126620. PubMed DOI

Da Rosa Guterres Z., Honda N.K., Coelho R.G., Alcantara G.B., Micheletti A.C. Antigenotoxicity of depsidones isolated from Brazilian lichens. Orbital. Electron. J. Chem. 2017;9:50–54. doi: 10.17807/orbital.v9i1.897. DOI

Brandão L.F.G., Alcantara G.B., Matos M.D.F.C., Bogo D., dos Santos Freitas D., Oyama N.M., Honda N.K. Cytotoxic evaluation of phenolic compounds from lichens against melanoma cells. Chem. Pharm. Bull. 2013;61:176–183. PubMed

Behera B.C., Mahadik N., Morey M. Antioxidative and cardiovascular-protective activities of metabolite usnic acid and psoromic acid produced by lichen species Usnea complanata under submerged fermentation. Pharm. Biol. 2012;50:968–979. doi: 10.3109/13880209.2012.654396. PubMed DOI

Deraeve C.L., Guo Z., Bon R.S., Blankenfeldt W., DiLucrezia R., Wolf A., Menninger S., Stigter E.A., Wetzel S., Choidas A. Psoromic acid is a selective and covalent rab-prenylation inhibitor targeting autoinhibited rabggtase. J. Am. Chem. Soc. 2012;134:7384–7391. doi: 10.1021/ja211305j. PubMed DOI

Clinical and Laboratory Standards Institute . Laboratory Detection and Identification of Mycobacteria. 1st ed. Clinical and Laboratory Standards Institute; Wayne, PA, USA: 2008. Approved Guideline; CLSI Document M48-A.

Clinical and Laboratory Standards Institute . Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. 2nd ed. CLSI; Wayne, PA, USA: 2011. Approved Standard M24-A2. PubMed

Semelková L., Janošcová P., Fernandes C., Bouz G., Janďourek O., Konečná K., Paterová P., Navrátilová L., Kuneš J., Doležal M. Design, synthesis, antimycobacterial evaluation, and in silico studies of 3-(phenylcarbamoyl)-pyrazine-2-carboxylic acids. Molecules. 2017;22:1491. doi: 10.3390/molecules22091491. PubMed DOI PMC

Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3. PubMed DOI

Zhang Q., Liu H.W. Studies of UDP-galactopyranose mutase from Escherichia coli: An unusual role of reduced fad in its catalysis. J. Am. Chem. Soc. 2000;122:9065–9070. doi: 10.1021/ja001333z. DOI

Veerapen N., Yuan Y., Sanders D.A., Pinto B.M. Synthesis of novel ammonium and selenonium ions and their evaluation as inhibitors of udp-galactopyranose mutase. Carbohydr. Res. 2004;339:2205–2217. doi: 10.1016/j.carres.2004.07.012. PubMed DOI

Abuhammad A., Lack N., Schweichler J., Staunton D., Sim R.B., Sim E. Improvement of the expression and purification of Mycobacterium tuberculosis arylamine N-acetyltransferase (TBNAT) a potential target for novel anti-tubercular agents. Protein Expr. Purif. 2011;80:246–252. doi: 10.1016/j.pep.2011.06.021. PubMed DOI

Brooke E.W., Davies S.G., Mulvaney A.W., Pompeo F., Sim E., Vickers R.J. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases. Bioorg. Med. chem. 2003;11:1227–1234. doi: 10.1016/S0968-0896(02)00642-9. PubMed DOI

Trott O., Olson A.J. Autodock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455–461. doi: 10.1002/jcc.21334. PubMed DOI PMC

Hassan S.T.S., Švajdlenka E. Biological evaluation and molecular docking of protocatechuic acid from Hibiscus sabdariffa L. As a potent urease inhibitor by an esi-ms based method. Molecules. 2017;22:1696. doi: 10.3390/molecules22101696. PubMed DOI PMC

BIOVIA D.S. Discovery Studio Modeling Environment. Dassault Systèmes; San Diego, CA, USA: 2016.

Ramis I.B., Vianna J.S., Reis A.J., von Groll A., Ramos D.F., Viveiros M., da Silva P.E.A. Antimicrobial and efflux inhibitor activity of usnic acid against Mycobacterium abscessus. Planta Med. 2018;6 doi: 10.1055/a-0639-5412. PubMed DOI

Fadipe V.O., Mongalo N.I., Opoku A.R., Dikhoba P.M., Makhafola T.J. Isolation of anti-mycobacterial compounds from Curtisia dentata (burm. F.) ca sm (curtisiaceae) BMC Complement. Altern. Med. 2017;17:306. doi: 10.1186/s12906-017-1818-9. PubMed DOI PMC

Ganihigama D.U., Sureram S., Sangher S., Hongmanee P., Aree T., Mahidol C., Ruchirawat S., Kittakoop P. Antimycobacterial activity of natural products and synthetic agents: Pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. Eur. J. Med. Chem. 2015;89:1–12. doi: 10.1016/j.ejmech.2014.10.026. PubMed DOI

Tasdemir D., Franzblau S.G. In vitro antituberculotic activity of several lichen metabolites. Planta Med. 2007;73:174. doi: 10.1055/s-2007-986955. DOI

Zhang Y., Permar S., Sun Z.H. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 2002;51:42–49. doi: 10.1099/0022-1317-51-1-42. PubMed DOI

Portaels F., Pattyn S.R. Growth of mycobacteria in relation to the pH of the medium. Ann. Microbiol. (Paris) 1982;133:213–221. PubMed

Yew W.W., Leung C.C. Antituberculosis drugs and hepatotoxicity. Respirology. 2006;11:699–707. doi: 10.1111/j.1440-1843.2006.00941.x. PubMed DOI

Chan R., Benet L.Z. Evaluation of the relevance of dili predictive hypotheses in early drug development: Review of in vitro methodologies vs. BDDCS classification. Toxicol. Res. 2018;7:358–370. doi: 10.1039/C8TX00016F. PubMed DOI PMC

Dykhuizen E.C., May J.F., Tongpenyai A., Kiessling L.L. Inhibitors of UDP-galactopyranose mutase thwart mycobacterial growth. J. Am. Chem. Soc. 2008;130:6706–6707. doi: 10.1021/ja8018687. PubMed DOI

Castagnolo D., de Logu A., Radi M., Bechi B., Manetti F., Magnani M., Supino S., Meleddu R., Chisu L., Botta M. Synthesis, biological evaluation and sar study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis. Bioorg. Med. Chem. 2008;16:8587–8591. doi: 10.1016/j.bmc.2008.08.016. PubMed DOI

Lo H.-H., Chung J. The effects of plant phenolics, caffeic acid, chlorogenic acid and ferulic acid on arylamine N-acetyltransferase activities in human gastrointestinal microflora. Anticancer Res. 1999;19:133–139. PubMed

Kukongviriyapan V., Phromsopha N., Tassaneeyakul W., Kukongviriyapan U., Sripa B., Hahnvajanawong V., Bhudhisawasdi V. Inhibitory effects of polyphenolic compounds on human arylamine N-acetyltransferase 1 and 2. Xenobiotica. 2006;36:15–28. doi: 10.1080/00498250500489901. PubMed DOI

Wang H.H., Chung J.G., Ho C.C., Wu L.T., Chang S.H. Aloe-emodin effects on arylamine N-acetyltransferase activity in the bacterium Helicobacter pylori. Planta Med. 1998;64:176–178. doi: 10.1055/s-2006-957399. PubMed DOI

Kawamura A., Graham J., Mushtaq A., Tsiftsoglou S.A., Vath G.M., Hanna P.E., Wagner C.R., Sim E. Eukaryotic arylamine N-acetyltransferase: Investigation of substrate specificity by high-throughput screening. Biochem. Pharm. 2005;69:347–359. doi: 10.1016/j.bcp.2004.09.014. PubMed DOI

Van Straaten K.E., Kuttiyatveetil J.R., Sevrain C.M., Villaume S.A., Jiménez-Barbero J.S., Linclau B., Vincent S.P.P., Sanders D.A. Structural basis of ligand binding to UDP-galactopyranose mutase from Mycobacterium tuberculosis using substrate and tetrafluorinated substrate analogues. J. Am. Chem. Soc. 2015;137:1230–1244. doi: 10.1021/ja511204p. PubMed DOI

Fullam E., Talbot J., Abuhammed A., Westwood I., Davies S.G., Russell A.J., Sim E. Design, synthesis and structure—Activity relationships of 3,5-diaryl-1H-pyrazoles as inhibitors of arylamine N-acetyltransferase. Bioorg. Med. Chem. Lett. 2013;23:2759–2764. doi: 10.1016/j.bmcl.2013.02.052. PubMed DOI

Abuhammad A., Fullam E., Lowe E.D., Staunton D., Kawamura A., Westwood I.M., Bhakta S., Garner A.C., Wilson D.L., Seden P.T. Piperidinols that show anti-tubercular activity as inhibitors of arylamine N-acetyltransferase: An essential enzyme for mycobacterial survival inside macrophages. PLoS ONE. 2012;7:e52790. doi: 10.1371/journal.pone.0052790. PubMed DOI PMC

Gruber T.D., Borrok M.J., Westler W.M., Forest K.T., Kiessling L.L. Ligand binding and substrate discrimination by UDP-galactopyranose mutase. J. Mol. Biol. 2009;391:327–340. doi: 10.1016/j.jmb.2009.05.081. PubMed DOI PMC

Rahim F., Zaman K., Ullah H., Taha M., Wadood A., Javed M.T., Rehman W., Ashraf M., Uddin R., Uddin I. Synthesis of 4-thiazolidinone analogs as potent in vitro anti-urease agents. Bioorg. Chem. 2015;63:123–131. doi: 10.1016/j.bioorg.2015.10.005. PubMed DOI

Brassicasterol with Dual Anti-Infective Properties against HSV-1 and Mycobacterium tuberculosis, and Cardiovascular Protective Effect: Nonclinical In Vitro and In Silico Assessments

A Microbiological, Toxicological, and Biochemical Study of the Effects of Fucoxanthin, a Marine Carotenoid, on Mycobacterium tuberculosis and the Enzymes Implicated in Its Cell Wall: A Link Between Mycobacterial Infection and Autoimmune Diseases

A Multi-Biochemical and In Silico Study on Anti-Enzymatic Actions of Pyroglutamic Acid against PDE-5, ACE, and Urease Using Various Analytical Techniques: Unexplored Pharmacological Properties and Cytotoxicity Evaluation

Psoromic Acid, a Lichen-Derived Molecule, Inhibits the Replication of HSV-1 and HSV-2, and Inactivates HSV-1 DNA Polymerase: Shedding Light on Antiherpetic Properties

In Vitro Study of Multi-Therapeutic Properties of Thymus bovei Benth. Essential Oil and Its Main Component for Promoting Their Use in Clinical Practice